Multidomain Cognitive Impairment in Children With Pseudotumor Cerebri Syndrome

J Neuroophthalmol. 2022 Mar 1;42(1):e93-e98. doi: 10.1097/WNO.0000000000001420. Epub 2022 Jan 4.

Abstract

Background: Although prompt and suitable treatment of pseudotumor cerebri syndrome (PTCS) leads to an excellent prognosis and can prevent optic nerve atrophy, adults show long-lasting neurocognitive deficits even with prompt treatment. The purpose of our study was to evaluate cognitive outcomes in pediatric patients with PTCS.

Methods: We performed a prospective study on children diagnosed with PTCS and a healthy control group. Children with pre-existing neurological conditions or psychiatric drug use were excluded. Both groups underwent a neurocognitive evaluation, using the NeuroTrax computerized battery of tests. The PTCS group were tested 3 months after the initial diagnosis.

Results: We evaluated 82 children (49 females [60%], 6.5-16 years old, mean age 13.3), including 26 diagnosed with idiopathic PTC and 56 controls. Global cognitive score (P < 0.001), verbal memory (P < 0.001), executive function (P < 0.001), attention (P< 0.003), and information processing speed (P < 0.004) were all significantly lower in the PTCS group. No differences were found between children currently being treated and those whose symptoms had resolved and treatment was stopped.

Conclusions: Children with PTCS experience comprehensive cognitive decline that persists after the resolution of the symptoms and treatment.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Cognitive Dysfunction* / diagnosis
  • Cognitive Dysfunction* / etiology
  • Female
  • Humans
  • Male
  • Prospective Studies
  • Pseudotumor Cerebri* / complications
  • Pseudotumor Cerebri* / diagnosis